MedTrace Logo

24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion

NCT02361242 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2016-02-15

No results posted yet for this study

Summary

PLEODIAL-II study is an extension of the previous pilot PLEODIAL-I study (CLN-PXT00864-03 protocol) and is designed for the descriptive analysis of patients with mild AD who are exposed to PXT00864 over an additional 24-week period.

Conditions

  • Alzheimer Disease

Interventions

DRUG

PXT00864

PXT00864 is a fixed-dose combination of baclofen and acamprosate

Sponsors & Collaborators

  • Ascopharm Groupe Novasco

    collaborator OTHER

  • Pharnext S.C.A.

    lead OTHER

Principal Investigators

  • Jean-Marc Orgogozo, MD · Hospital Pellegrin, Bordeaux, France

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02361242 on ClinicalTrials.gov